Citeline Report – Executing Early Phase Research In Hematological Oncology: What Matters To Biotech?

Early phase studies are a critical stepping-stone, as they are the first time an investigational medicinal product (IMP) is tested on humans. They are complex to execute, and any mistakes can be incredibly costly for sponsors looking to progress closer to commercialization. For smaller biopharma companies with limited financial resources, expertise, and significant pressure from investors, the stakes are particularly high. Pharma Intelligence and Allucent conducted a survey of biotechs in the hematological oncology space to understand the challenges they have faced in their early-phase research, what support they need to execute trials successfully, and what the future of these studies looks like.